Earnings ·
NexGel reported Q2 2026 revenue of $3.69 million and a net loss of $2.87 million, driven by integration costs from its…
NXGLWNexgel, Inc.
NexGel reported Q2 2026 revenue of $3.69 million and a net loss of $2.87 million, driven by integration costs from its mid-April acquisition of Celularity and a strategic recall of SilverSeal inventory for hospital market launch. The company faces supply chain constraints resulting in a BioNX Surgical backlog of approximately $795,000. Additionally, the proxy solicitation to increase authorized shares and approve a reverse stock split failed due to broker non-votes linked to a redomicile proposal; management plans to resolicit these votes as standalone items by late September. NexGel operates in the healthcare and consumer products industry, manufacturing hydrogel-based medical and aesthetic devices.